Healthcare Pharma brings anticancer medicine

Healthcare Pharmaceuticals Limited (HPL) has recently launched US-based Eli Lilly and Company's anticancer drug "Cyramza™" in Bangladesh. 

The drug is approved as a single agent or in combination with other agents for cancers arising from stomach, lungs, liver or large bowel that have spread to distant parts of the body, said a press release.

"We are pleased to bring to Bangladesh an option for the first-line treatment of people with metastatic non-small cell lung cancer (NSCLC) and second line treatment for people living with the burden of gastric cancer," said Luca Visini, managing director of ELC.

"We believe this will help us in moving several steps ahead in our collective goal to make lung and gastric cancer a less formidable challenge and a condition that can be managed," said Visini.

"Healthcare Pharmaceuticals Limited is committed to bringing specialised care to Bangladesh for people living with chronic conditions such as diabetes and cancer," said Bhupati Kumar Roy, executive director marketing of the HPL.